ZOMP

ZOMP is a life science technology company that emerged from the University of Cambridge in February 2022. It focuses on advancing cell analysis and sorting through its innovative 3D imaging flow cytometry technology. Co-founded by Professor Steven Lee, Dr. Kevin O’Holleran, and Gillies Kleboe, ZOMP commercializes academic research to develop a new instrument that combines the speed of flow cytometry with the high-resolution imaging typically associated with microscopy. The company's core product is a 3D imaging flow cytometer that captures high-quality, whole-cell images at subcellular resolution. This technology offers a significant increase in sensitivity compared to traditional imaging cytometers, enabling rapid and detailed cellular analysis. ZOMP's technology has applications in important biomedical fields such as immunotherapy, drug discovery, and cancer diagnosis, aiming to enhance diagnostic accuracy and accelerate research and development in these areas. The company has secured £2 million in seed funding to support product development and expansion efforts.

• Employees 9
• Founded 2023
• Annual Revenue $2400000
• Total Funding $3121505